alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Home › Research › Topics › molecular-basis

molecular-basis

2 studies tagged molecular-basis, dated 2015-04-16 to 2017-03-08. Bibliography: BibTeX (.bib) · RIS (.ris)

Newest in this topic

  1. Genetics of Migraine: Insights into the Molecular Basis of Migraine Disorders 2017-03-08
  2. Molecular basis for mid-region amyloid-β capture by leading Alzheimer's disease immunotherapies 2015-04-16

Studies

2 studies carry this tag.

Date range

2015 to 2017

Top journals

  • Headache 1
  • Scientific reports 1

Newest first, then by address. Each study has a usefulness score out of 100 (rubric version 4.0); tap a score to see what makes it up. Tags were assigned automatically from each study's title and summary. The same studies as a filter in the library.

  1. Genetics of Migraine: Insights into the Molecular Basis of Migraine Disorders

    ✓ Peer-reviewed alzhub usefulness score 38 out of 100. Headache 2017-03-08 Genetics

    Migraine is a complex, debilitating neurovascular disorder, typically characterized by recurring, incapacitating attacks of severe headache often accompanied by nausea and neurological disturbances.

  2. Molecular basis for mid-region amyloid-β capture by leading Alzheimer's disease immunotherapies

    ✓ Peer-reviewed alzhub usefulness score 40 out of 100. Scientific reports 2015-04-16 Treatments

    Solanezumab (Eli Lilly) and crenezumab (Genentech) are the leading clinical antibodies targeting Amyloid-β (Aβ) to be tested in multiple Phase III clinical trials for the prevention of Alzheimer's disease in at-risk individuals.

All topic tags with their study counts